HIV and opioid treatment study halted early – what we know

NCT ID NCT04480554

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether different medications for opioid use disorder (methadone, buprenorphine/naloxone, or naltrexone) could reduce immune system inflammation in people with HIV. Researchers measured changes in blood markers of immune activation over 24 weeks. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Methadone, buprenorphine/naloxone, or extended-release naltrexone

What this could lead to

If successful, this could help doctors choose the best medication for opioid use disorder to improve immune recovery in people with HIV.

What could go wrong

The study was terminated early, so results are limited. It was a small Phase 2 trial, and findings may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Inflammation inflammatory disease opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Go Vap Clinic

    Ho Chi Minh City, Vietnam

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States